Clinical Trial

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Study acronym: KEYNOTE-603
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2017-10-13; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2025-11-25
Status change: Active, Not Recruiting → Recruiting 2024-01-04
Status change: Recruiting → Active, Not Recruiting 2023-02-22
Trial Details
NCT Number NCT03313778
Lead Sponsor ModernaTX, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Solid Tumors
Enrollment 161 participants
Start Date 2017-08-14
Primary Completion 2027-11-21 (estimated)
Study Completion 2027-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-04